## Kate A Dolan

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7108514/publications.pdf

Version: 2024-02-01

		47006	5	54911
151	7,899	47		84
papers	citations	h-index		g-index
154	154	154		9138
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
2	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
3	Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet, The, 2016, 388, 1089-1102.	13.7	458
4	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
5	Fourâ€year followâ€up of imprisoned male heroin users and methadone treatment: mortality, reâ€incarceration and hepatitis C infection. Addiction, 2005, 100, 820-828.	3.3	223
6	The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet, The, 2016, 388, 1228-1248.	13.7	213
7	HIV in prison in low-income and middle-income countries. Lancet Infectious Diseases, The, 2007, 7, 32-41.	9.1	210
8	A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence, 2003, 72, 59-65.	3.2	169
9	Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet, The, 2016, 388, 1115-1126.	13.7	157
10	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 2010, 52, 1216-1224.	7.3	156
11	An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug and Alcohol Review, 2004, 23, 213-217.	2.1	152
12	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. Journal of Infectious Diseases, 2004, 189, 1846-1855.	4.0	147
13	Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug and Alcohol Review, 2000, 19, 337-346.	2.1	135
14	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology, 2003, 32, 717-724.	1.9	129
15	Prisonâ€based syringe exchange programmes: a review of international research and development. Addiction, 2003, 98, 153-158.	3.3	122
16	Drug consumption facilities: an update since 2000. Drug and Alcohol Review, 2003, 22, 227-233.	2.1	117
17	Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 2007, 91, 228-235.	3.2	117
18	Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Medical Journal of Australia, 1997, 166, 127-130.	1.7	113

#	Article	IF	CITATIONS
19	Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997. Medical Journal of Australia, 2000, 172, 57-61.	1.7	103
20	Substance Use and HIV Among Female Sex Workers and Female Prisoners. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, S110-S117.	2.1	103
21	Effect of prisonâ€based opioid substitution treatment and postâ€release retention in treatment on risk of reâ€incarceration. Addiction, 2012, 107, 372-380.	3.3	89
22	Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. Aids, 1989, 3, 267-272.	2.2	84
23	Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction, 2001, 96, 1289-1296.	3.3	81
24	Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination?. Drug and Alcohol Review, 2003, 22, 317-321.	2.1	77
25	HIV transmission in a prison system in an Australian State. Medical Journal of Australia, 1999, 171, 14-17.	1.7	76
26	Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug and Alcohol Review, 1998, 17, 153-158.	2.1	75
27	Incidence and risk for acute hepatitis C infection during imprisonment in Australia. European Journal of Epidemiology, 2010, 25, 143-148.	<b>5.7</b>	74
28	Sexual behaviour of injecting drug users and associated risks of HIV infection for Non-injecting sexual partners. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1989, 1, 51-58.	1.2	73
29	HIV, prisoners, and human rights. Lancet, The, 2016, 388, 1202-1214.	13.7	72
30	People who inject drugs in prison: HIV prevalence, transmission and prevention. International Journal of Drug Policy, 2015, 26, S12-S15.	3.3	71
31	Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health, 2010, 10, 633.	2.9	69
32	Syringe exchange schemes for drug users in England and Scotland. BMJ: British Medical Journal, 1988, 296, 1717-1719.	2.3	68
33	HIV prevalence and risk behaviour in needle exchange attenders: a national study. Medical Journal of Australia, 1997, 166, 237-240.	1.7	68
34	A Literature Review of International Implementation of Opioid Substitution Treatment in Prisons: Equivalence of Care?. European Addiction Research, 2009, 15, 107-112.	2.4	64
35	Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country. Asian Journal of Psychiatry, 2015, 16, 78-83.	2.0	64
36	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005â€2014: The ⟨scp⟩HITS⟨/scp⟩â€p study. Journal of Viral Hepatitis, 2017, 24, 733-741.	2.0	61

#	Article	IF	Citations
37	Life-style factors and social circumstances of syringe sharing in injecting drug users. Addiction, 1992, 87, 993-1003.	3.3	60
38	Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian Journal of Psychiatry, 2015, 16, 17-25.	2.0	59
39	Methadone maintenance reduces injecting in prison. BMJ: British Medical Journal, 1996, 312, 1162-1162.	2.3	59
40	A prospective study of hepatitis <scp>C</scp> incidence in Australian prisoners. Addiction, 2014, 109, 1695-1706.	3.3	58
41	Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Medical Journal of Australia, 2001, 174, 183-184.	1.7	57
42	Decreased heroin availability in Sydney in early 2001. Addiction, 2003, 98, 93-95.	3.3	57
43	Dynamic Models of Infectious Disease Transmission in Prisons and the General Population. Epidemiologic Reviews, 2018, 40, 40-57.	3.5	57
44	Survey of drug consumption rooms: service delivery and perceived public health and amenity impact. Drug and Alcohol Review, 2005, 24, 21-24.	2.1	55
45	Drug Use and Its Correlates in an Australian Prisoner Population. Addiction Research and Theory, 2003, 11, 89-101.	1.9	53
46	AIDS behind bars. Aids, 1995, 9, 825-832.	2.2	52
47	Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health, 2006, 14, 120-125.	1.5	52
48	Smoking in Correctional Settings Worldwide: Prevalence, Bans, and Interventions. Epidemiologic Reviews, 2018, 40, 82-95.	3.5	49
49	Prevalence of Drug Injection, Sexual Activity, Tattooing, and Piercing Among Prison Inmates. Epidemiologic Reviews, 2018, 40, 58-69.	3.5	48
50	Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduction Journal, 2006, 3, 2.	3.2	47
51	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 2015, 26, 976-983.	3.3	44
52	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
53	Hiv Risk Behaviour of Idus Before, During and After Imprisonment in New South Wales. Addiction Research, 1996, 4, 151-160.	0.6	42
54	HIV and Viral Hepatitis Among Imprisoned Key Populations. Epidemiologic Reviews, 2018, 40, 12-26.	3.5	42

#	Article	IF	CITATIONS
55	Injecting drug users' understanding of hepatitis C. Addictive Behaviors, 2008, 33, 1602-1605.	3.0	41
56	Initiation to heroin injecting among heroin users in Sydney, Australia: cross sectional survey. Harm Reduction Journal, 2005, 2, 2.	3.2	40
57	HIV Transmission Risk Behaviour of Clients Attending Syringe-exchange Schemes in England and Scotland. Addiction, 1988, 83, 1449-1455.	3.3	38
58	Effect of pegylated interferonâ€Î±â€2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 957-965.	2.8	38
59	Value for money in drug treatment: economic evaluation of prison methadone. Drug and Alcohol Dependence, 2006, 84, 160-166.	3.2	37
60	Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012. Emerging Infectious Diseases, 2015, 21, 765-774.	4.3	37
61	Global Prison Health Care Governance and Health Equity: A Critical Lack of Evidence. American Journal of Public Health, 2020, 110, 303-308.	2.7	37
62	Hepatitis C transmission and HIV postâ€exposure prophylaxis after needleâ€Âand syringeâ€sharing in Australian prisons. Medical Journal of Australia, 2003, 178, 546-549.	1.7	35
63	Characteristics of Iranian Women Seeking Drug Treatment. Journal of Women's Health, 2011, 20, 1687-1691.	3.3	35
64	Evaluation of the Condom Distribution Program in New South Wales Prisons, Australia. Journal of Law, Medicine and Ethics, 2004, 32, 124-128.	0.9	34
65	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduction Journal, 2017, 14, 19.	3.2	33
66	A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug and Alcohol Review, 2017, 36, 305-310.	2.1	32
67	An International Review of Methadone Provision in Prisons. Addiction Research, 1996, 4, 85-97.	0.6	31
68	Transmitted/Founder Viruses Rapidly Escape from CD8 <sup>+</sup> T Cell Responses in Acute Hepatitis C Virus Infection. Journal of Virology, 2015, 89, 5478-5490.	3.4	31
69	Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers. Medical Journal of Australia, 1987, 147, 275-276.	1.7	30
70	Drug Injecting and Syringe Sharing in Custody and in the Community: An Exploratory Survey of HIV Risk Behaviour. Howard Journal of Criminal Justice, 1990, 29, 177-186.	0.7	27
71	Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review. Journal of Adolescent Health, 2018, 62, S18-S26.	2,5	27
72	A bleach program for inmates in NSW: an HIV prevention strategy. Australian and New Zealand Journal of Public Health, 1998, 22, 838-840.	1.8	26

#	Article	IF	Citations
73	Shooting Gallery Operation in the Context of Establishing a Medically Supervised Injecting Center: Sydney, Australia. Journal of Urban Health, 2007, 84, 255-266.	3.6	26
74	Evidence of HIV transmission in an Australian prison. Medical Journal of Australia, 1994, 160, 734-734.	1.7	25
75	The establishment of a methadone treatment clinic for women in Tehran, Iran. Journal of Public Health Policy, 2011, 32, 219-230.	2.0	25
76	Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs?. Drug and Alcohol Review, 2004, 23, 281-286.	2.1	23
77	HIV education in a Siberian prison colony for drug dependent males. International Journal for Equity in Health, 2004, 3, 7.	3.5	23
78	Six-month follow-up of Iranian women in methadone treatment: drug use, social functioning, crime, and HIV and HCV seroincidence. Substance Abuse and Rehabilitation, 2012, 3, 37.	4.8	23
79	Risk Factors for Hepatitis C Infection and Perception of Antibody Status among Male Prison Inmates in the Hepatitis C Incidence and Transmission in Prisons Study Cohort, Australia. Journal of Urban Health, 2004, 81, 448-452.	3.6	21
80	Can hepatitis C transmission be reduced in Australian prisons?. Medical Journal of Australia, 2001, 174, 378-379.	1.7	20
81	Prisoners coâ€infected with tuberculosis and HIV: a systematic review. Journal of the International AIDS Society, 2016, 19, 20960.	3.0	20
82	A managed alcohol program in Sydney, Australia: Acceptability, costâ€savings and nonâ€beverage alcohol use. Drug and Alcohol Review, 2018, 37, S184-S194.	2.1	20
83	Estimating the number of people who inject drugs and syringe coverage in Australia, 2005–2016. Drug and Alcohol Dependence, 2019, 197, 108-114.	3.2	20
84	Maternal and neonatal complications of substance abuse in Iranian pregnant women. Acta Medica Iranica, 2012, 50, 411-6.	0.8	20
85	Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern. Asian Journal of Psychiatry, 2018, 31, 49-55.	2.0	18
86	Availability, Accessibility, and Coverage of Needle and Syringe Programs in Prisons in the European Union. Epidemiologic Reviews, 2020, 42, 19-26.	3.5	17
87	A mathematical model of HIV transmission in NSW prisons. Drug and Alcohol Dependence, 1998, 50, 197-202.	3.2	16
88	HIV risk behaviour and prevention in prison: a bleach programme for inmates in NSW. Drug and Alcohol Review, 1999, 18, 139-143.	2.1	16
89	Women-only drug treatment services and needs in Iran: the first review of current literature. DARU, Journal of Pharmaceutical Sciences, 2016, 24, 3.	2.0	16
90	Opioid use, treatment and harm reduction services: the first report from the Persian Gulf region. Journal of Substance Use, 2014, , 1-7.	0.7	15

#	Article	IF	CITATIONS
91	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS ONE, 2016, 11, e0150655.	2.5	15
92	Per-Event Probability of Hepatitis C Infection during Sharing of Injecting Equipment. PLoS ONE, 2014, 9, e100749.	2.5	14
93	Compulsory detoxification is a major challenge to harm reduction in China. International Journal of Drug Policy, 2010, 21, 165-166.	3.3	13
94	Hepatitis Câ€specific effector and regulatory <scp>CD</scp> 4 Tâ€cell responses are associated with the outcomes of primary infection. Journal of Viral Hepatitis, 2016, 23, 985-993.	2.0	13
95	A Randomized Controlled Trial of Brief Cognitive Behavioral Therapy for Regular Methamphetamine Use in Methadone Treatment. Journal of Psychoactive Drugs, 2019, 51, 280-289.	1.7	13
96	Evidence of HIV transmission in an Australian prison. Medical Journal of Australia, 1994, 161, 509-509.	1.7	12
97	A review of HIV prevention among young injecting drug users: A guide for researchers. Harm Reduction Journal, 2005, 2, 5.	3.2	12
98	What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal for Equity in Health, 2005, 4, 5.	3.5	11
99	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. BMJ Open, 2018, 8, e020723.	1.9	11
100	Reductions in HIV risk behaviour and stable HIV prevalence in syringe-exchange clients and other injectors in England. Drug and Alcohol Review, 1993, 12, 133-142.	2.1	10
101	Evaluation of a prisonâ€based naltrexone program. International Journal of Prisoner Health, 2007, 3, 214-224.	0.9	10
102	An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia. Addiction Research and Theory, 2008, 16, 607-617.	1.9	10
103	HIV and Hepatitis C Virus Infection and Risk Behaviors Among Heterosexual, Bisexual, and Lesbian Women Who Inject Drugs in Australia. LGBT Health, 2015, 2, 127-134.	3.4	10
104	Public health alternatives to incarceration for drug offenders. Eastern Mediterranean Health Journal, 2017, 23, 222-230.	0.8	10
105	HIV testing, and the care and treatment of HIV positive people in English prisons. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1993, 5, 199-206.	1.2	9
106	Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promotion Journal of Australia, 2006, 17, 70-72.	1.2	9
107	The Mortality After Release from Incarceration Consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis. International Journal of Population Data Science, 2020, 5, 1145.	0.1	9
108	An exploratory study of needlestick injuries among Australian prison officers. International Journal of Prisoner Health, 2008, 4, 164-168.	0.9	8

#	Article	IF	Citations
109	Prisoners should not be left behind in HCV research and policies. Harm Reduction Journal, 2020, 17, 33.	3.2	8
110	Is a syringe exchange feasible in a prison setting?. Medical Journal of Australia, 1996, 164, 508-508.	1.7	7
111	Characteristics of Aboriginal Injecting Drug Users in Sydney, Australia: Prison History, Hepatitis C Status and Drug Treatment Experiences. Journal of Ethnicity in Substance Abuse, 2004, 2, 51-58.	0.9	7
112	Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care. Australian and New Zealand Journal of Public Health, 2008, 32, 86-87.	1.8	7
113	Presence of hepatitis C virus in syringes confiscated in prisons in Australia. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1655-1657.	2.8	7
114	A review of HIV in prisons in Nepal. Kathmandu University Medical Journal, 2010, 7, 351-354.	0.2	7
115	HIV Responses in Arab States on the Southern Persian Gulf Border: The First Review. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, 10, e5392.	0.4	7
116	Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment. Addiction and Health, 2016, 8, 90-97.	0.2	7
117	Hair analysis underestimates heroin use in prisoners. Drug and Alcohol Review, 2006, 25, 425-431.	2.1	6
118	HIV in Indian prisons: risk behaviour, prevalence, prevention & treatment. Indian Journal of Medical Research, 2010, 132, 696-700.	1.0	6
119	Detection of drugs in Australian prisons: supply reduction strategies. International Journal of Prisoner Health, 2014, 10, 111-117.	0.9	5
120	Drug and alcohol use and treatment for Australian Indigenous and non-Indigenous prisoners: demand reduction strategies. International Journal of Prisoner Health, 2015, 11, 30-38.	0.9	5
121	Brief intervention on Smoking, Nutrition, Alcohol and Physical (SNAP) inactivity for smoking relapse prevention after release from smoke-free prisons: a study protocol for a multicentre, investigator-blinded, randomised controlled trial. BMJ Open, 2018, 8, e021326.	1.9	5
122	Social and structural determinants of health associated with drug use patterns among female sex workers in Iran: A latent class analysis. International Journal of Drug Policy, 2021, 91, 102798.	3.3	5
123	Determinants of Consistent Condom Use Among Iranians Living with HIV/AIDS: Implication for Prevention. International Journal of High Risk Behaviors & Addiction, 2017, 6, .	0.2	5
124	[Commentary] PRISON RESEARCH. Addiction, 2009, 104, 223-223.	3.3	4
125	Health service provision for disease control among prisoners: a conceptual note. Journal of Health Research, 2020, 34, 353-358.	0.8	4
126	Veiled Truths: Iranian Women and Risky Sexual Behavior in the Context of Substance Use. Journal of Reproduction and Infertility, 2018, 19, 237-246.	1.0	4

#	Article	IF	CITATIONS
127	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. Eurosurveillance, 2021, 26, .	7.0	4
128	8.5 HIV prevention in the community: injecting drug users. Medical Journal of Australia, 1996, 165, 266-267.	1.7	3
129	Examining HIV, drug use and risk behaviours: A case study in the custodial settings of Thailand and Indonesia. International Journal of Prisoner Health, 2009, 5, 180-191.	0.9	3
130	Compulsory treatment of drug users in Asia: designed to torture?. International Journal of Prisoner Health, 2015, 11, 255-268.	0.9	3
131	Natural killer cells in highly exposed hepatitis Câ€seronegative injecting drug users. Journal of Viral Hepatitis, 2016, 23, 464-472.	2.0	3
132	Views of Iranian prison staff towards needle-exchange program in prison. Drugs: Education, Prevention and Policy, 2016, 23, 113-119.	1.3	3
133	Is there a role for contact tracing in preventing HIV transmission among injecting drug users?. Addiction, 1996, 91, 917-919.	3.3	3
134	A randomised controlled trial of motivational interview for relapse prevention after release from smoke-free prisons in Australia. International Journal of Prisoner Health, 2021, 17, 462-476.	0.9	3
135	Supporting needle and syringe programs in Australia. Australian and New Zealand Journal of Public Health, 2001, 25, 187-187.	1.8	2
136	Monitoring a Prison Opioid Treatment Program Over a Period of Change to Clinical Governance Arrangements, 2007–2013. Journal of Substance Abuse Treatment, 2016, 70, 58-63.	2.8	2
137	HIV/AIDS, hepatitis and tuberculosis-related mortality among incarcerated people: a global scoping review. International Journal of Prisoner Health, 2021, ahead-of-print, 66-82.	0.9	2
138	Methamphetamine Use Disorder Untreated among Women in Methadone Treatment in Iran. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, In Press, .	0.4	2
139	A Volatile Time for British Drug Policies: commentary on the Editorial by Alan Glanz. Addiction, 1988, 83, 1241-1242.	3.3	1
140	Is a syringe exchange feasible in a prison setting?. Medical Journal of Australia, 1996, 165, 59-59.	1.7	1
141	Perceptions of substance use, treatment options and training needs among Iranian primary care physicians. International Journal for Equity in Health, 2005, 4, 7.	3.5	1
142	HIV Testing Among Lesbian Women: Social Contexts and Subjective Meanings. Journal of Homosexuality, 2008, 54, 307-324.	2.0	1
143	The development and evaluation of stimulant treatment programmes. Current Opinion in Psychiatry, 2015, 28, 280-285.	6.3	1
144	Trends in cancer incidence and survival for Indigenous and nonâ€Indigenous people in the Northern Territory. Medical Journal of Australia, 2017, 207, 46-46.	1.7	1

#	Article	IF	CITATION
145	National and sub-national HIV/AIDS-related mortality in Iran, 1990–2015: a population-based modeling study. International Journal of STD and AIDS, 2019, 30, 1362-1372.	1.1	1
146	Comparison of Characteristics of Methamphetamine Versus Opiate Users in Tehran, Iran. International Journal of High Risk Behaviors & Addiction, 2016, 5, .	0.2	1
147	Therapeutic Community Program for Opioid-Dependent Treatment Seekers. Iranian Journal of Psychiatry and Behavioral Sciences, $2017,11,1$	0.4	1
148	Opioid Use among Women on a Stable Methadone Dose. Iranian Journal of Psychiatry and Behavioral Sciences, 2017, $11$ , .	0.4	1
149	P4.109â€Narcotics are cheaper than food in pakistan: our pwids are dying from aids. , 2017, , .		O
150	Shining light on darkness: suicidal ideation and suicide attempt among Iranian women who do and do not use drugs. Drugs: Education, Prevention and Policy, 2021, 28, 349-356.	1.3	0
151	Methamphetamine Use Disorder Untreated among Women in Methadone Treatment in Iran. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, In Press, .	0.4	0